PIP rupture data back French call for explantation and entrench EU regulatory response gap
This article was originally published in Clinica
Executive Summary
Over a fifth of the 8,500 purely precautionary PIP explantations conducted in France up to July 2012 revealed undetected ruptures, according to a report by the national regulatory agency, ANSM. These and other findings further vindicate the agency’s much-criticised preventive explantation policy – which pitted the agency against other countries, such as the UK and Australia – the report concludes.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.